Menopausal Hormone Therapy: Where Do We Go From Here?

The recent early termination of the Prempro arm of the Women's Health Initiative (WHI) has provoked discussion and controversy among well-informed clinicians regarding patients' use of hormone therapy (HT). In this issue of Journal Watch Women's Health, 2 members of our editorial board present their views. Dr. Andrew Kaunitz, a clinician who provides individualized gynecologic care to menopausal women, suggests that the study findings do not apply to progestins other than medroxyprogesterone acetate. Dr. Christine Berg, a clinician who provides care to cancer patients, particularly those with breast cancer, counters that the entire class of oral compounds should be considered to possibly bear the same risks as Prempro. Their dialogue remind…